The Biotech That Has Almost Doubled in 2017 With the Potential to Boom Even More Post author:Sam Post published:November 21, 2017 Post category:BioPharma Keith Speights, writing for The Motley Fool, notes one biotech that’s booming. Source: BioSpace You Might Also Like Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017 ViewRay Rakes in $26.1 Million in Private Placement January 18, 2017 How This Little Biopharma Could Beat Amgen, Teva to the Migraine Finish Line January 16, 2018
Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017
